SCHEMBL6835347

SCHEMBL6835347

O=C(O)c1ccc2c(c1)C(=O)C(Cc1cccc(Cl)c1)[S+]([O-])N2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 1/20 0.40
RXRB P28702 1/20 0.40
RXRG P48443 1/20 0.40
PDE5A O76074 1/20 0.40
NR4A2 P43354 1/20 0.40
TAS2R14 Q9NYV8 1/20 0.39
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
HCAR2 Q8TDS4 1/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
POLB P06746 1/20 0.36
GPR55 Q9Y2T6 1/20 0.36
KDM4A O75164 1/20 0.36
KDM4C Q9H3R0 1/20 0.36
KDM5B Q9UGL1 1/20 0.36
MEN1 O00255 1/20 0.36
HPGD P15428 1/20 0.36
KMT2A Q03164 1/20 0.36
MRGPRX4 Q96LA9 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6831723 0.89 ALDH1A1 (0.38) NR4A2ALDH1A1MAPTMRGPRX4
SCHEMBL6680629 0.89 KMT2A (0.40) MAPTPOLBMEN1HPGDKMT2A
SCHEMBL6837169 0.87 NR4A2 (0.40) NR4A2TAS2R14ALDH1A1MAPTHCAR2
SCHEMBL6834783 0.86 TSHR (0.40)
SCHEMBL6831785 0.85 KDM4E (0.36) KDM5BMRGPRX4
SCHEMBL6835570 0.84 GRK6 (0.34) ALDH1A1KDM4CKDM5B
SCHEMBL6835278 0.83 KDM5A (0.35) KDM5BMRGPRX4
SCHEMBL6831840 0.82 TP53 (0.42) MAPTRAB9APOLB
SCHEMBL6835323 0.77 RXRA (0.39) RXRARXRBRXRGPDE5ANR4A2
SCHEMBL6678743 0.77 RXRA (0.43) RXRARXRBRXRGPDE5ANR4A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040043985-A1 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors HICKS JAMES LESTER (US) 2004-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040043985-A1 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors MMP13, MMP26, MMP9 RXRA 1763/4885RXRB 1654/4885RXRG 1771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.